inositol has been researched along with Inflammatory Bowel Diseases in 2 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
Inflammatory Bowel Diseases: Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients who received mesalamine plus the mixture of beta-glucan, inositol and digestive enzymes (group A) reported a reduction in abdominal pain together with reduction in bloating and flatulence after four weeks of treatment." | 9.24 | Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome. ( Cosco, C; Cosco, V; Doldo, P; Garieri, P; Mancina, RM; Ruggiero, G; Spagnuolo, R, 2017) |
| "Patients who received mesalamine plus the mixture of beta-glucan, inositol and digestive enzymes (group A) reported a reduction in abdominal pain together with reduction in bloating and flatulence after four weeks of treatment." | 5.24 | Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome. ( Cosco, C; Cosco, V; Doldo, P; Garieri, P; Mancina, RM; Ruggiero, G; Spagnuolo, R, 2017) |
| "Chronic inflammation is a well-recognized risk factor for the development of human cancer." | 1.35 | Inflammatory bowel disease: a model of chronic inflammation-induced cancer. ( Liao, J; Taboada, S; Yang, GY, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Spagnuolo, R | 1 |
| Cosco, C | 1 |
| Mancina, RM | 1 |
| Ruggiero, G | 1 |
| Garieri, P | 1 |
| Cosco, V | 1 |
| Doldo, P | 1 |
| Yang, GY | 1 |
| Taboada, S | 1 |
| Liao, J | 1 |
1 trial available for inositol and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome.
Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; beta-Glucans; Biological Factors; Drug Comb | 2017 |
1 other study available for inositol and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
Inflammatory bowel disease: a model of chronic inflammation-induced cancer.
Topics: Animals; Antineoplastic Agents; Antioxidants; Cell Transformation, Neoplastic; Colorectal Neoplasms; | 2009 |